Laurie Bibens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laurie Bibens has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Dassonville-Klimpt
Faculty of Pharmacy, Agents Infectieux, Résistance et Chimiothérapie (AGIR), UR 4294, University of Picardie Jules Verne, F-80025 Amiens, France
2 shared publications - Jean-Paul Becker
AGIR (Agents Infectieux, Résistance et Chimiothérapie), UR4294, UFR de Pharmacie, Université de Picardie Jules Verne, 1 Rue des Louvels, 80037 Amiens, France
2 shared publications - Pascal Sonnet
Faculty of Pharmacy, Agents Infectieux, Résistance et Chimiothérapie (AGIR), UR 4294, UFR de Pharmacie, University of Picardie Jules Verne, F-80037 Amiens, France
2 shared publications - Céline Damiani
AGIR, UR 4294, Université de Picardie Jules Verne, 80025 Amiens, France
1 shared publication - François Peltier
AGIR, EA 4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France
1 shared publication - Nadine Lemaître
Laboratoire de Bactériologie-Hygiène, Centre Hospitalier Universitaire, Lille, France
1 shared publication
Latest Publications
- Open Access
- 10 March 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (3) , 425
A Review of Fatty Acid Biosynthesis Enzyme Inhibitors as Promising Antimicrobial Drugs
Resistance to antimicrobial drugs is currently a serious threat to human health. Consequently, we are facing an urgent need for new antimicrobial drugs acting with original modes of action. The ubiquitous and widely conserved microbial fatty acid biosynthesis pathway, called FAS-II system, represents a potential target to tackle antimicrobial resistance. This pathway has been extensively studied, and eleven proteins have been described. FabI (or InhA, its homologue in mycobacteria) was considered as a prime target by many teams and is currently the only enzyme with commercial inhibitor drugs: triclosan and isoniazid. Furthermore, afabicin and CG400549, two promising compounds which also target FabI, are in clinical assays to treat Staphylococcus aureus. However, most of the other enzymes are still underexploited targets. This review, after presenting the FAS-II system and its enzymes in Escherichia coli, highlights the reported inhibitors of the system. Their biological activities, main interactions formed with their targets and structure–activity relationships are presented as far as possible.
- 10 March 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (3) , 425
Open AccessA Review of Fatty Acid Biosynthesis Enzyme Inhibitors as Promising Antimicrobial Drugs
Resistance to antimicrobial drugs is currently a serious threat to human health. Consequently, we are facing an urgent need for new antimicrobial drugs acting with original modes of action. The ubiquitous and widely conserved microbial fatty acid biosynthesis pathway, called FAS-II system, represents a potential target to tackle antimicrobial resistance. This pathway has been extensively studied, and eleven proteins have been described. FabI (or InhA, its homologue in mycobacteria) was considered as a prime target by many teams and is currently the only enzyme with commercial inhibitor drugs: triclosan and isoniazid. Furthermore, afabicin and CG400549, two promising compounds which also target FabI, are in clinical assays to treat Staphylococcus aureus. However, most of the other enzymes are still underexploited targets. This review, after presenting the FAS-II system and its enzymes in Escherichia coli, highlights the reported inhibitors of the system. Their biological activities, main interactions formed with their targets and structure–activity relationships are presented as far as possible.
- Open Access
- 1 November 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 14 (1) , 88
Design, Synthesis and Antimicrobial Activities of Quinoline-Based FabZ Inhibitors as Promising Antimicrobial Drugs
At present, antimicrobial resistance is one of the most significant public health challenges
- 1 November 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 14 (1) , 88
Open AccessDesign, Synthesis and Antimicrobial Activities of Quinoline-Based FabZ Inhibitors as Promising Antimicrobial Drugs
At present, antimicrobial resistance is one of the most significant public health challenges